PubMed

Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.

Lund SS, Tarnow L, Frandsen M, Nielsen BB, Hansen BV, Pedersen O, Parving HH, Vaag AA.

BMJ. 2009 Nov 9;339:b4324. doi: 10.1136/bmj.b4324.PMID: 19900993 [PubMed - in process]Related articlesFree article

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease.

Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; the TREAT Investigators.

N Engl J Med. 2009 Nov 19;361(21):2019-2032. Epub 2009 Oct 30.PMID: 19880844 [PubMed - as supplied by publisher]Related articlesFree article

Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity.

Tarnow I, Michelson AD, Barnard MR, Frelinger AL 3rd, Aasted B, Jensen BR, Parving HH, Rossing P, Tarnow L.

Platelets. 2009 Nov;20(7):513-9.PMID: 19852691 [PubMed - in process]Related articles

Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria.

Weir MR, Hollenberg NK, Zappe DH, Meng X, Parving HH, Viberti G, Remuzzi G.

J Hypertens. 2009 Oct 3. [Epub ahead of print]PMID: 19809363 [PubMed - as supplied by publisher]Related articles

Telomere length predicts all-cause mortality in patients with type 1 diabetes.

Astrup AS, Tarnow L, Jorsal A, Lajer M, Nzietchueng R, Benetos A, Rossing P, Parving HH.

Diabetologia. 2009 Oct 4. [Epub ahead of print]PMID: 19802713 [PubMed - as supplied by publisher]Related articles

Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria.

Delea TE, Sofrygin O, Palmer JL, Lau H, Munk VC, Sung J, Charney A, Parving HH, Sullivan SD.

J Am Soc Nephrol. 2009 Oct;20(10):2205-13. Epub 2009 Sep 17.PMID: 19762496 [PubMed - indexed for MEDLINE]Related articles

Dual renin-angiotensin system blockade and kidney disease.

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Pfeffer MA.

J Am Coll Cardiol. 2009 Jul 14;54(3):278-9; author reply 279-80. No abstract available. PMID: 19589445 [PubMed - indexed for MEDLINE]Related articles

Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria.

Persson F, Rossing P, Reinhard H, Juhl T, Stehouwer CD, Schalkwijk C, Danser AH, Boomsma F, Frandsen E, Parving HH.

Diabetes Care. 2009 Oct;32(10):1873-9. Epub 2009 Jul 8.PMID: 19587362 [PubMed - in process]Related articles

Functional annotations of diabetes nephropathy susceptibility loci through analysis of genome-wide renal gene expression in rat models of diabetes mellitus.

Hu Y, Kaisaki PJ, Argoud K, Wilder SP, Wallace KJ, Woon PY, Blancher C, Tarnow L, Groop PH, Hadjadj S, Marre M, Parving HH, Farrall M, Cox RD, Lathrop M, Vionnet N, Bihoreau MT, Gauguier D.

BMC Med Genomics. 2009 Jul 9;2:41.PMID: 19586551 [PubMed - in process]Related articlesFree article

Autoregulation of glomerular filtration rate during spironolactone treatment in hypertensive patients with type 1 diabetes: a randomized crossover trial.

Schjoedt KJ, Christensen PK, Jorsal A, Boomsma F, Rossing P, Parving HH.

Nephrol Dial Transplant. 2009 Nov;24(11):3343-9. Epub 2009 Jun 26.PMID: 19561152 [PubMed - in process]Related articles

Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes.

Lund SS, Tarnow L, Astrup AS, Hovind P, Jacobsen PK, Alibegovic AC, Parving I, Pietraszek L, Frandsen M, Rossing P, Parving HH, Vaag AA.

Diabetes Obes Metab. 2009 Oct;11(10):966-77. Epub 2009 Jun 25.PMID: 19558610 [PubMed - in process]Related articles

Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).

Robinson JG, Ballantyne CM, Grundy SM, Hsueh WA, Parving HH, Rosen JB, Adewale AJ, Polis AB, Tomassini JE, Tershakovec AM.

Am J Cardiol. 2009 Jun 15;103(12):1694-702.PMID: 19539078 [PubMed - indexed for MEDLINE]Related articles

The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristics.

Lambers Heerspink HJ, Agarwal R, Coyne DW, Parving HH, Ritz E, Remuzzi G, Audhya P, Amdahl MJ, Andress DL, de Zeeuw D.

Am J Nephrol. 2009;30(3):280-6. Epub 2009 Jun 15.PMID: 19521070 [PubMed - in process]Related articles

Tubular and glomerular injury in diabetes and the impact of ACE inhibition.

Nielsen SE, Sugaya T, Tarnow L, Lajer M, Schjoedt KJ, Astrup AS, Baba T, Parving HH, Rossing P.

Diabetes Care. 2009 Sep;32(9):1684-8. Epub 2009 Jun 5.PMID: 19502542 [PubMed - indexed for MEDLINE]Related articles

Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill J, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, Uno H; TREAT Investigators.

Am J Kidney Dis. 2009 Jul;54(1):59-69. Epub 2009 Jun 5.PMID: 19501439 [PubMed - indexed for MEDLINE]Related articles

Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.

Bilous R, Chaturvedi N, Sjølie AK, Fuller J, Klein R, Orchard T, Porta M, Parving HH.

Ann Intern Med. 2009 Jul 7;151(1):11-20, W3-4. Epub 2009 May 18.PMID: 19451554 [PubMed - indexed for MEDLINE]Related articles

Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study.

Hovind P, Rossing P, Tarnow L, Johnson RJ, Parving HH.

Diabetes. 2009 Jul;58(7):1668-71. Epub 2009 May 1.PMID: 19411615 [PubMed - indexed for MEDLINE]Related articlesFree article

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.

Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, Zannad F; AURORA Study Group.

N Engl J Med. 2009 Apr 2;360(14):1395-407. Epub 2009 Mar 30.PMID: 19332456 [PubMed - indexed for MEDLINE]Related articlesFree article

[Aliskiren combined with losartan in type 2-diabetes and nephropathy - secondary publication]

Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK.

Ugeskr Laeger. 2009 Mar 9;171(11):881-4. Danish. PMID: 19291865 [PubMed]Related articles

Short-term oral treatment with the angiotensin II receptor antagonist losartan does not improve coronary vasomotor function in asymptomatic type 2 diabetes patients.

Kjaer A, Kristoffersen US, Tarnow L, Parving HH, Hesse B.

Diabetes Res Clin Pract. 2009 Apr;84(1):34-8. Epub 2009 Feb 23.PMID: 19233497 [PubMed - indexed for MEDLINE]Related articles

Expression, localization, and function of the thioredoxin system in diabetic nephropathy.

Advani A, Gilbert RE, Thai K, Gow RM, Langham RG, Cox AJ, Connelly KA, Zhang Y, Herzenberg AM, Christensen PK, Pollock CA, Qi W, Tan SM, Parving HH, Kelly DJ.

J Am Soc Nephrol. 2009 Apr;20(4):730-41. Epub 2009 Feb 11.PMID: 19211714 [PubMed - indexed for MEDLINE]Related articles

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA.

Nephrol Dial Transplant. 2009 May;24(5):1663-71. Epub 2009 Jan 14.PMID: 19145003 [PubMed - indexed for MEDLINE]Related articles

Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial.

Schjoedt KJ, Astrup AS, Persson F, Frandsen E, Boomsma F, Rossing K, Tarnow L, Rossing P, Parving HH.

Diabetologia. 2009 Jan;52(1):46-9. Epub 2008 Oct 31.PMID: 18974967 [PubMed - indexed for MEDLINE]Related articles

Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study.

Lund SS, Tarnow L, Astrup AS, Hovind P, Jacobsen PK, Alibegovic AC, Parving I, Pietraszek L, Frandsen M, Rossing P, Parving HH, Vaag AA.

PLoS One. 2008;3(10):e3363. Epub 2008 Oct 9.PMID: 18852875 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial.

Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Chaturvedi N; DIRECT Programme Study Group.

Lancet. 2008 Oct 18;372(9647):1385-93. Epub 2008 Sep 25.PMID: 18823658 [PubMed - indexed for MEDLINE]Related articles

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials.

Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjølie AK; DIRECT Programme Study Group.

Lancet. 2008 Oct 18;372(9647):1394-402. Epub 2008 Sep 25.PMID: 18823656 [PubMed - indexed for MEDLINE]Related articles

Microalbuminuria and obesity: impact on cardiovascular disease and mortality.

Klausen KP, Parving HH, Scharling H, Jensen JS.

Clin Endocrinol (Oxf). 2009 Jul;71(1):40-5. Epub 2008 Sep 18.PMID: 18803675 [PubMed - indexed for MEDLINE]Related articles

Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy.

Jorsal A, Tarnow L, Flyvbjerg A, Parving HH, Rossing P, Rasmussen LM.

Diabetologia. 2008 Nov;51(11):2100-7. Epub 2008 Aug 22.PMID: 18719882 [PubMed - indexed for MEDLINE]Related articles

G/T substitution in intron 1 of the UNC13B gene is associated with increased risk of nephropathy in patients with type 1 diabetes.

Trégouet DA, Groop PH, McGinn S, Forsblom C, Hadjadj S, Marre M, Parving HH, Tarnow L, Telgmann R, Godefroy T, Nicaud V, Rousseau R, Parkkonen M, Hoverfält A, Gut I, Heath S, Matsuda F, Cox R, Kazeem G, Farrall M, Gauguier D, Brand-Herrmann SM, Cambien F, Lathrop M, Vionnet N; EURAGEDIC Consortium.

Diabetes. 2008 Oct;57(10):2843-50. Epub 2008 Jul 15.PMID: 18633107 [PubMed - indexed for MEDLINE]Related articlesFree article

A combined abnormality in heart rate variation and QT corrected interval is a strong predictor of cardiovascular death in type 1 diabetes.

Lykke JA, Tarnow L, Parving HH, Hilsted J.

Scand J Clin Lab Invest. 2008 Apr 12:1-6. [Epub ahead of print]PMID: 18609100 [PubMed - as supplied by publisher]Related articles

Sustained postprandial decrease in plasma levels of LDL cholesterol in patients with type-2 diabetes mellitus.

Lund SS, Petersen M, Frandsen M, Smidt UM, Parving HH, Vaag AA, Jensen T.

Scand J Clin Lab Invest. 2008 Apr 16:1-14. [Epub ahead of print]PMID: 18609081 [PubMed - as supplied by publisher]Related articles

Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study.

Persson F, Rossing P, Hovind P, Stehouwer CD, Schalkwijk CG, Tarnow L, Parving HH.

Scand J Clin Lab Invest. 2008;68(8):731-8.PMID: 18609080 [PubMed - indexed for MEDLINE]Related articles

Aliskiren combined with losartan in type 2 diabetes and nephropathy.

Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators.

N Engl J Med. 2008 Jun 5;358(23):2433-46.PMID: 18525041 [PubMed - indexed for MEDLINE]Related articlesFree article

Elevated levels of high-molecular-weight adiponectin in type 1 diabetes.

Leth H, Andersen KK, Frystyk J, Tarnow L, Rossing P, Parving HH, Flyvbjerg A.

J Clin Endocrinol Metab. 2008 Aug;93(8):3186-91. Epub 2008 May 27.PMID: 18505763 [PubMed - indexed for MEDLINE]Related articlesFree article

Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy.

Jorsal A, Tarnow L, Frystyk J, Lajer M, Flyvbjerg A, Parving HH, Vionnet N, Rossing P.

Kidney Int. 2008 Sep;74(5):649-54. Epub 2008 May 21.PMID: 18496510 [PubMed - indexed for MEDLINE]Related articles

The PPAR gamma 2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy.

Jorsal A, Tarnow L, Lajer M, Ek J, Hansen T, Pedersen O, Parving HH.

Mol Genet Metab. 2008 Jul;94(3):347-51. Epub 2008 May 7.PMID: 18467141 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study.

Gaede P, Valentine WJ, Palmer AJ, Tucker DM, Lammert M, Parving HH, Pedersen O.

Diabetes Care. 2008 Aug;31(8):1510-5. Epub 2008 Apr 28.PMID: 18443195 [PubMed - indexed for MEDLINE]Related articlesFree article

Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes.

Lund SS, Tarnow L, Stehouwer CD, Schalkwijk CG, Teerlink T, Gram J, Winther K, Frandsen M, Smidt UM, Pedersen O, Parving HH, Vaag AA.

Eur J Endocrinol. 2008 May;158(5):631-41.PMID: 18426821 [PubMed - indexed for MEDLINE]Related articlesFree article

Long-term prevention of diabetic nephropathy: an audit.

Schjoedt KJ, Hansen HP, Tarnow L, Rossing P, Parving HH.

Diabetologia. 2008 Jun;51(6):956-61. Epub 2008 Apr 3.PMID: 18385971 [PubMed - indexed for MEDLINE]Related articles

Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy.

Nguyen TQ, Tarnow L, Jorsal A, Oliver N, Roestenberg P, Ito Y, Parving HH, Rossing P, van Nieuwenhoven FA, Goldschmeding R.

Diabetes Care. 2008 Jun;31(6):1177-82. Epub 2008 Mar 14.PMID: 18344285 [PubMed - indexed for MEDLINE]Related articlesFree article

Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes.

Persson F, Rossing P, Schjoedt KJ, Juhl T, Tarnow L, Stehouwer CD, Schalkwijk C, Boomsma F, Frandsen E, Parving HH.

Kidney Int. 2008 Jun;73(12):1419-25. Epub 2008 Mar 12.PMID: 18337712 [PubMed - indexed for MEDLINE]Related articles

Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate.

Astrup AS, Tarnow L, Pietraszek L, Schalkwijk CG, Stehouwer CD, Parving HH, Rossing P.

Diabetes Care. 2008 Jun;31(6):1170-6. Epub 2008 Mar 10.PMID: 18332153 [PubMed - indexed for MEDLINE]Related articlesFree article

Increased renal gene transcription of protein kinase C-beta in human diabetic nephropathy: relationship to long-term glycaemic control.

Langham RG, Kelly DJ, Gow RM, Zhang Y, Cox AJ, Qi W, Thai K, Pollock CA, Christensen PK, Parving HH, Gilbert RE.

Diabetologia. 2008 Apr;51(4):668-74. Epub 2008 Feb 16.PMID: 18278479 [PubMed - indexed for MEDLINE]Related articles

Effect of a multifactorial intervention on mortality in type 2 diabetes.

Gaede P, Lund-Andersen H, Parving HH, Pedersen O.

N Engl J Med. 2008 Feb 7;358(6):580-91.PMID: 18256393 [PubMed - indexed for MEDLINE]Related articlesFree article

Relation of left ventricular function, mass, and volume to NT-proBNP in type 1 diabetic patients.

Astrup AS, Kim WY, Tarnow L, Botnar RM, Simonsen C, Brix L, Pietraszek L, Hansen PR, Manning WJ, Parving HH.

Diabetes Care. 2008 May;31(5):968-70. Epub 2008 Feb 5.PMID: 18252905 [PubMed - indexed for MEDLINE]Related articlesFree article

Plasma alpha-defensin is associated with cardiovascular morbidity and mortality in type 1 diabetic patients.

Joseph G, Tarnow L, Astrup AS, Hansen TK, Parving HH, Flyvbjerg A, Frystyk J.

J Clin Endocrinol Metab. 2008 Apr;93(4):1470-5. Epub 2008 Jan 22.PMID: 18211979 [PubMed - indexed for MEDLINE]Related articlesFree article

ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy.

Parving HH, de Zeeuw D, Cooper ME, Remuzzi G, Liu N, Lunceford J, Shahinfar S, Wong PH, Lyle PA, Rossing P, Brenner BM.

J Am Soc Nephrol. 2008 Apr;19(4):771-9. Epub 2008 Jan 16.PMID: 18199798 [PubMed - indexed for MEDLINE]Related articlesFree article

Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.

Lund SS, Tarnow L, Frandsen M, Smidt UM, Pedersen O, Parving HH, Vaag AA.

Eur J Endocrinol. 2008 Jan;158(1):35-46.PMID: 18166815 [PubMed - indexed for MEDLINE]Related articlesFree article

A combined abnormality in heart rate variation and QT corrected interval is a strong predictor of cardiovascular death in type 1 diabetes.

Lykke JA, Tarnow L, Parving HH, Hilsted J.

Scand J Clin Lab Invest. 2008;68(7):654-9.PMID: 19378439 [PubMed - indexed for MEDLINE]Related articles

Sustained postprandial decrease in plasma levels of LDL cholesterol in patients with type-2 diabetes mellitus.

Lund SS, Petersen M, Frandsen M, Smidt UM, Parving HH, Vaag AA, Jensen T.

Scand J Clin Lab Invest. 2008;68(7):628-40.PMID: 19378436 [PubMed - indexed for MEDLINE]Related articles